David M. Mott - 12 Aug 2022 Form 4 Insider Report for Epizyme, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 12 Aug 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Aug 2022, 18:59:01 UTC
Prior SEC filing: 01 Jul 2022
Next SEC filing: 17 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ John Weidenbruch, attorney-in-fact

Key filing fact

David M. Mott filed Form 4 for Epizyme, Inc. on 16 Aug 2022.

Key facts

This page summarizes David M. Mott's Form 4 filing for Epizyme, Inc..
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 16 Aug 2022, 18:59.

Change

Previous filing in this sequence was filed on 01 Jul 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EPZM transaction

Common Stock, par value $0.0001

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -215,494
Change %: -96%
Price
Shares after: 8,994
Date: 12 Aug 2022
Ownership: Direct
Footnotes: F1

EPZM transaction

Common Stock, par value $0.0001

Disposed to Issuer

Transaction value
Shares: -8,994
Change %: -100%
Price
Shares after: 0
Date: 12 Aug 2022
Ownership: Direct
Footnotes: F2

EPZM transaction

Common Stock, par value $0.0001

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -106,959
Change %: -100%
Price
Shares after: 0
Date: 12 Aug 2022
Ownership: See Note
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David M. Mott is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.

Footnote F2

Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

Footnote F3

The shares are directly held by the David Mott Declaration of Trust dated May 31, 2001 as amended (the "Mott Trust"). The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the Mott Trust shares in which the Reporting Person has no pecuniary interest.